Xian Deng
Stock Analyst at UBS
(4.51)
# 1,006
Out of 4,408 analysts
167
Total ratings
63.4%
Success rate
17.1%
Average return
Main Sectors:
Stocks Rated by Xian Deng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0NZT UCB SA | Maintained: Buy | €330.00 | $273.80 | +20.53% | 23 | Jun 9, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €137.00 → €170.00 | $156.20 | +8.83% | 23 | May 19, 2026 | |
| ARGX argenx SE | Maintained: Hold | $850 | $884.20 | -3.87% | 33 | May 8, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Hold | n/a | $757.80 | - | 12 | May 8, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $118 → $113 | $44.70 | +153.44% | 3 | May 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Hold | €30.00 | $25.08 | +19.62% | 4 | Apr 1, 2026 | |
| LON: 0MGB Genmab A/S | Rated: Buy | kr 2,750 → kr 2,600 | $1,616.00 | +60.89% | 36 | Mar 26, 2026 | |
| SWX: BIOV BioVersys AG | Initiated Coverage: Buy | CHF 48.00 | $26.20 | +83.21% | 2 | Dec 11, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 720.00 → CHF 605.00 | $495.00 | n/a | 12 | Feb 6, 2023 | |
| FRA: MDG1 Medigene AG | Maintained: Buy | €8.00 | $0.0188 | n/a | 6 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | kr 480.00 → kr 450.00 | $536.16 | n/a | 7 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 255.00 | $194.61 | n/a | 2 | Feb 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €31.00 | $20.80 | n/a | 4 | Nov 1, 2019 |
UCB SA
Jun 9, 2026
Maintained: Buy
Price Target: €330.00
Current: $273.80
Upside: +20.53%
Ipsen S.A.
May 19, 2026
Maintained: Hold
Price Target: €137.00 → €170.00
Current: $156.20
Upside: +8.83%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: $850
Current: $884.20
Upside: -3.87%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $757.80
Upside: -
Zealand Pharma A/S
May 8, 2026
Maintained: Buy
Price Target: $118 → $113
Current: $44.70
Upside: +153.44%
Lakefront Biotherapeutics NV
Apr 1, 2026
Maintained: Hold
Price Target: €30.00
Current: $25.08
Upside: +19.62%
Genmab A/S
Mar 26, 2026
Rated: Buy
Price Target: kr 2,750 → kr 2,600
Current: $1,616.00
Upside: +60.89%
BioVersys AG
Dec 11, 2025
Initiated Coverage: Buy
Price Target: CHF 48.00
Current: $26.20
Upside: +83.21%
Lonza Group AG
Feb 6, 2023
Maintained: Buy
Price Target: CHF 720.00 → CHF 605.00
Current: $495.00
Upside: n/a
Medigene AG
Aug 4, 2022
Maintained: Buy
Price Target: €8.00
Current: $0.0188
Upside: n/a
May 26, 2020
Downgraded: Hold
Price Target: kr 480.00 → kr 450.00
Current: $536.16
Upside: n/a
Feb 17, 2020
Maintained: Buy
Price Target: kr 255.00
Current: $194.61
Upside: n/a
Nov 1, 2019
Maintained: Buy
Price Target: €31.00
Current: $20.80
Upside: n/a